DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Actiq (Fentanyl Citrate Oral Transmucosal) - Published Studies

 
 



Actiq Related Published Studies

Well-designed clinical trials related to Actiq (Fentanyl Oral Transmucosal)

Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer. [2011.06.01]

Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 microg in healthy volunteers. [2010.12]

Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. [2010.02]

Oral transmucosal fentanyl citrate: a novel analgesic agent for use in retinal photocoagulation. [2009.11]

A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries. [2007.08]

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. [2007.06.18]

Oral transmucosal fentanyl citrate versus placebo for painful dressing changes: a crossover trial. [2007.03]

Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. [2006.05]

The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. [2004.11]

Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. [2004.09]

Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. [2004.04]

A double-blind study of the analgesic efficacy of oral transmucosal fentanyl citrate and oral morphine in pediatric patients undergoing burn dressing change and tubbing. [2003.11]

A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. [2003.08]

A comparison of oral transmucosal fentanyl and oral midazolam for premedication in children. [2002.08]

A randomized, clinical trial of oral midazolam plus placebo versus oral midazolam plus oral transmucosal fentanyl for sedation during laceration repair. [2002.05]

A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. [2002.01]

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). [2001.03]

Oral transmucosal fentanyl pretreatment for outpatient general anesthesia. [2000.03]

Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. [2000.03]

The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. [1999.09]

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. [1999.02]

Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. [1998.10]

Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. [1998.04.15]

Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. [1998.02]

Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. [1998.01]

Oral transmucosal fentanyl citrate as an additional premedicant for adult cardiac surgery patients. [1997.10]

Effects of anesthetic technique on side effects associated with fentanyl Oralet premedication. [1997.08]

The safety and efficacy of oral transmucosal fentanyl citrate for preoperative sedation in young children. [1996.12]

Comparison of oral transmucosal fentanyl citrate and intramuscular meperidine, promethazine, and chlorpromazine for conscious sedation of children undergoing laceration repair. [1996.10]

Oral transmucosal fentanyl citrate for premedication in adults. [1996.01]

The use of oral transmucosal fentanyl citrate for painful procedures in children. [1995.03]

Oral transmucosal fentanyl citrate for preanaesthetic medication of paediatric cardiac surgery patients. [1995]

Oral transmucosal fentanyl citrate for premedication of children undergoing laceration repair. [1994.12]

Oral transmucosal fentanyl citrate premedication in patients undergoing outpatient dermatologic procedures. [1994.12]

Oral transmucosal fentanyl citrate (OTFC) for the treatment of postoperative pain. [1993.02]

Oral transmucosal fentanyl citrate for preanesthetic medication of pediatric day surgery patients with and without droperidol as a prophylactic anti-emetic. [1992.01]

Oral transmucosal fentanyl citrate for premedication in paediatric outpatients. [1990.11]

The effects of oral transmucosal fentanyl citrate premedication on preoperative behavioral responses and gastric volume and acidity in children. [1989.09]

Preanesthetic medication in children: a comparison of oral transmucosal fentanyl citrate versus placebo. [1989.09]

Comparison of oral transmucosal fentanyl citrate and an oral solution of meperidine, diazepam, and atropine for premedication in children. [1989.04]

Well-designed clinical trials possibly related to Actiq (Fentanyl Oral Transmucosal)

A comparison of four sedation techniques for pediatric dental surgery. [2010.10]

A comparison of change in the 0-10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. [2010.06]

Opioids for the management of breakthrough (episodic) pain in cancer patients. [2006.01.25]

The effect of premedication with OTFC, with or without ondansetron, on postoperative agitation, and nausea and vomiting in pediatric ambulatory patients. [2004.09]

Clinically important changes in acute pain outcome measures: a validation study. [2003.05]

Defining the clinically important difference in pain outcome measures. [2000.12.01]

Consequences of inadequate analgesia during painful procedures in children. [1998.02]

Other research related to Actiq (Fentanyl Oral Transmucosal)

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. [2012]

Fentanyl nasal spray for the treatment of cancer pain. [2011.07]

Rampant caries from oral transmucosal fentanyl citrate lozenge abuse. [2011.04]

Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. [2011.03]

Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. [2011]

[Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate]. [2010.07]

Rationales behind the choice of administration form with fentanyl: Delphi survey among Danish general practitioners. [2010.07]

Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. [2010.07]

Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. [2010.05]

Formulations of fentanyl for the management of pain. [2010]

Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. [2010]

A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. [2009.11]

Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study. [2009.11]

Factors in the choice of oral transmucosal fentanyl citrate dose for adult burns dressings. [2009.09]

ORAL TRANSMUCOSAL FENTANYL CITRATE: A Novel Analgesic Agent for Use in Retinal Photocoagulation. [2009.08.19]

Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. [2009]

Clinical rationale for administering fentanyl to cancer pain patients: two Delphi surveys of pain management experts in Denmark. [2008.11]

Pharmacokinetics of buccal mucosal administration of fentanyl in a carboxymethylcellulose gel compared with IV administration in dogs. [2008.09]

Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series. [2008.05]

Association of transdermal fentanyl and oral transmucosal fentanyl citrate in the treatment of opioid naive patients with severe chronic noncancer pain. [2008.03]

Fentanyl buccal tablet. [2008.01]

[Oral transmucosal fentanyl citrate for the treatment of breakthrough pain. Results of a non-interventional study (NIS)] [2007.11]

The use of oral transmucosal fentanyl citrate during high-dose-rate gynecologic brachytherapy. [2007.08]

Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain? [2007.08]

Actiq: an effective oral treatment for cancer-related breakthrough pain. [2007.07]

Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). [2007.04]

Weighing in on the off-label use of Actiq for noncancer-related pain: a recipe for success or a recipe for disaster? [2007.03]

Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. [2007.03]

Accidental prehension and suspected transmucosal or oral absorption of fentanyl from a transdermal patch in a dog. [2007.01]

Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. [2007]

Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review. [2006.11.03]

Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002-2004). [2006.10]

Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. [2006.07]

A descriptive case series: oral transmucosal fentanyl use in patients with noncancerous pain. [2006.03]

Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. [2006]

Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. [2005.07]

Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. [2005.05]

Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. [2005.03]

Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. [2004.12]

Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate. [2004.10]

Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series. [2004.09]

Clinical effects and plasma concentrations of fentanyl after transmucosal administration in three species of great ape. [2004.06]

Oral transmucosal abuse of transdermal fentanyl. [2004.06]

Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series. [2004.05]

Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. [2003.10]

Uptake pharmacokinetics of the Fentanyl Oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. [2002.09]

Self-treatment with oral transmucosal fentanyl citrate to prevent emergency room visits for pain crises: patient self-reports of efficacy and utility. [2002]

Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. [2001.07]

[Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain] [2000.09.25]

A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. [1998.11]

Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. [1998.06]

A review of oral transmucosal fentanyl citrate: potent, rapid and noninvasive opioid analgesia. [1998.03]

Oral transmucosal fentanyl citrate as an anaesthetic premedication when dosed to an opioid effect vs total opioid consumption. [1998]

Oral transmucosal fentanyl citrate for analgesia and sedation in the emergency department. [1991.10]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012